Viracta Therapeutics Inc lost $1.32 per diluted share in fiscal year 2023. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2023 through Q3 FY2024, the same line adds up to a loss of $1.10 per diluted share. The table below carries 15 fiscal years, from 2009 to 2023, and the quarters Viracta Therapeutics Inc has filed alongside them.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Viracta Therapeutics Inc lost $1.32 per diluted share in fiscal year 2023.
Viracta Therapeutics Inc (VIRX) reported a loss of $1.30 per diluted share in fiscal year 2022 and a loss of $1.32 per diluted share in fiscal year 2023. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Viracta Therapeutics Inc (VIRX) reported a loss of $1.10 per diluted share over the trailing 12 months, Q4 FY2023 through Q3 FY2024, summed from the four most recent quarterly filings.
Viracta Therapeutics Inc (VIRX) reported -$0.27 in diluted earnings per share in Q3 2024. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Viracta Therapeutics Inc (VIRX) reported on that line in every period on record.
